Insomnia. nature, diagnosis, and treatment

Handbook of Clinical Neurology

Volumn 99, Issue C, 2011, Pages 723-746

  Morin, Charles M ^a   Benca, Ruth M ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNOTIC SEDATIVE AGENT;

ANIMAL; BOOK; CLASSIFICATION; COGNITIVE THERAPY; DIFFERENTIAL DIAGNOSIS; HUMAN; INSOMNIA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY;

ANIMALS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPNOTICS AND SEDATIVES; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 78149368688     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52007-4.00004-7     Document Type: Book

References (161)

1. Aden G.C., Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry 1983, 44:454-456.
2. Allen R.P., Mendels J., Nevins, et al. Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol 1987, 27:768-775.
3. American Academy of Sleep Medicine International Classification of Sleep Disorders: Diagnostic and Coding Manuel 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd edn.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC.
5. Ancoli-Israel S., Cole R., Alessi C., et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003, 26:342-392.
6. Asnis G.M., Chakraburtty A., DuBoff E.A., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999, 60:668-676.
7. Avidan A.Y., Fries B.E., James M.L., et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005, 53:955-962.
8. Bastien C.H., Vallières A., Morin C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001, 2:297-307.
9. Bastien C.H., Vallieres A., Morin C.M. Precipitating factors of insomnia. Behav Sleep Med 2004, 2:50-62.
10. Bastien C.H., St-Jean G., Morin C.M., et al. Chronic psychophysiological insomnia: hyperarousal and/or inhibition deficits? An ERPs investigation. Sleep 2008, 31:887-898.
11. Benca R.M., Obermeyer W.H., Thisted R.A., et al. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry 1992, 49:651-668.
12. Besset A., Villemin E., Tafti M., et al. Homeostatic process and sleep spindles in patients with sleep-maintenance insomnia: effect of partial (21h) sleep deprivation. Electroencephalogr Clin Neurophysiol 1998, 107:122-132.
13. Bonnet M.H., Arand D.L. Hyperarousal and insomnia. Sleep Med Rev 1997, 1:97-108.
14. Bootzin R.R., Epstein D., Wood J.M. Stimulus control instructions. Case Studies in Insomnia 1991, 19-28. Plenum Press, New York. P. Hauri (Ed.).
15. Borbely A.A., Youmbi-Balderer G. Effect of diphenhydramine on subjective sleep parameters and on motor activity during bedtime. Int J Clin Pharmacol 1988, 26:392-396.
16. Brassington G.S., King A.C., Bliwise D.L. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 2000, 48:1234-1240.
17. Breslau N., Roth T., Rosenthal L., et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996, 39:411-418.
18. Brzezinski A. Melatonin in humans. N Engl J Med 1997, 336:186-195.
19. Buysse D.J., Reynolds C.F., Kupfer D.J., et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994, 17:630-637.
20. Buysse D.J., Bate G., Kirkpatrick P. Fresh from the pipeline: ramelteon. Nat Rev Drug Discov 2005, 4:881-882.
21. Buysse D.J., Ancoli-Israel S., Edinger J.D., et al. Recommendations for a standard research assessment of insomnia. Sleep 2006, 29:1155-1173.
22. Buysse D.J., Thompson W., Scott J., et al. Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment. Sleep Med 2007, 8:198-208.
23. Buysse D.J., Angst J., Gamma A., et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008, 31:473-480.
24. Casale T.B., Blaiss M.S., Gelfand E., et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003, 111:S835-S842.
25. Cohn J.B., Wilcox C.S., Bremner J., et al. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol 1991, 31:747-750.
26. Cohrs S., Rodenbeck A., Guan Z., et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 2004, 174:421-429.
27. Currie S.R., Wilson K.G., Pontefract A.J., et al. Cognitive-behavioral treatment of insomnia secondary to chronic pain. J Consult Clin Psychol 2000, 68:407-416.
28. Czapinski P., Blaszczyk B., Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005, 5:3-14.
29. Daley M., Morin C.M., Leblanc M., et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms and good sleepers. Sleep 2009, 32:55-64.
30. Dashevsky B.A., Kramer M. Behavioral treatment of chronic insomnia in psychiatrically ill patients. J Clin Psychiatry 1998, 59:693-699.
31. Dauvilliers Y., Morin C.M., Cervena K., et al. Family studies in insomnia. J Psychosom Res 2005, 58:271-278.
32. Devoto A., Manganelli S., Lucidi F., et al. Quality of sleep and P300 amplitude in primary insomnia: a preliminary study. Sleep 2005, 28:859-863.
33. Dundar Y., Boland A., Strobl J., et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004, 8:1-125. iii-x.
34. Edinger J.D., Wohlgemuth W.K., Radtke R.A., et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001, 285:1856-1864.
35. Edinger J.D., Bonnet M.H., Bootzin R.R., et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep 2004, 27:1567-1596.
36. Edinger J.D., Wohlgemuth W.K., Krystal A.D., et al. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med 2005, 165:2527-2535.
37. Edinger J.D., Wohlgemuth W.K., Radtke R.A., et al. Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial. Sleep 2007, 30:203-212.
38. Elie R., Ruther E., Farr I., et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999, 60:536-544.
39. Erman M., Seiden D., Zammit G., et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006, 7:17-24.
40. Espie C.A. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annu Rev Psychol 2002, 53:215-243.
41. Espie C.A., MacMahon K.M., Kelly H.L., et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep 2007, 30:574-584.
42. Espie C.A., Fleming L., Cassidy J., et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008, 26:4651-4658.
43. Fava M., McCall W.V., Krystal A., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006, 59:1052-1060.
44. Foldvary-Schaefer N., De Leon Sanchez I., Karafa M., et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002, 43:1493-1497.
45. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention. JAMA 1989, 262:1479-1484.
46. Fry J., Scharf M., Mangano R., et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000, 15:141-152.
47. Glass J., Lanctot K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005, 331:1169.
48. Harvey A.G., Sharpley A.L., Ree M.J., et al. An open trial of cognitive therapy for chronic insomnia. Behav Res Ther 2007, 45:2491-2501.
49. Hauri P.J. Can we mix behavioral therapy with hypnotics when treating insomniacs?. Sleep 1997, 20:1111-1118.
50. Hauri P.J., Fisher J. Persistent psychophysiologic (learned) insomnia. Sleep 1986, 9:38-53.
51. Hauri P.J., Olmstead E. Childhood-onset insomnia. Sleep 1980, 3:59-65.
52. Hernandez Lara R., Del Rosal P.L., Ponce M.C. Short-term study of quazepam 15 milligrams in the treatment of insomnia. J Int Med Res 1983, 11:162-166.
53. Hindmarch I., Dawson J., Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005, 28:187-193.
54. Holbrook A.M., Crowther R., Lotter A., et al. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. Can Med Assoc J 2000, 162:216-220.
55. Holbrook A.M., Crowther R., Lotter A., et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000, 162:225-233.
56. Irwin M.R., Cole J.C., Nicassio P.M. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006, 25:3-14.
57. Jacobs G.D., Pace-Schott E.F., Stickgold R., et al. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004, 164:1888-1896.
58. Johnson E.O., Roehrs T., Roth T., et al. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998, 21:178-186.
59. Jones B.T., Macphee L.M., Broomfield N.M., et al. Sleep-related attentional bias in good, moderate, and poor (primary insomnia) sleepers. J Abnorm Psychol 2005, 114:249-258.
60. Kales A., Manfredi R.L., Vgontzas A.N., et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991, 49:468-476.
61. Karam-Hage M., Brower K.J. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci 2003, 57:542-544.
62. Kelly K.D., Pickett W., Yiannakoulias N., et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003, 32:503-509.
63. Klink M.E., Quan S.F., Kaltenborn W.T., et al. Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia. Arch Intern Med 1992, 152:1634-1637.
64. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26:793-799.
65. Krystal A.D., Erman M., Zammit G.K., et al. Long-term efficacy and safety of zolpidem extended-release 12.5mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008, 31:79-90.
66. Lamarche C.H., Ogilvie R.D. Electrophysiological changes during the sleep onset period of psychophysiological insomniacs, psychiatric insomniacs, and normal sleepers. Sleep 1997, 20:724-733.
67. Legros B., Bazil C.W. Effects of antiepileptic drugs on sleep architecture: a pilot study. Sleep Med 2003, 4:51-55.
68. Lewy A.J., Ahmed S., Jackson J.M., et al. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992, 9:380-392.
69. Lewy A.J., Emens J.S., Lefler B.J., et al. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 2005, 22:1093-1106.
70. Lichstein K.L., Wilson N.M., Johnson C.T. Psychological treatment of secondary insomnia. Psychol Aging 2000, 15:232-240.
71. Littner M., Kushida C.A., Anderson W.M., et al. Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep 2003, 26:337-341.
72. Mauri M.C., Gianetti S., Pugnetti L., et al. Quazepam versus triazolam in patients with sleep disorders: a double-blind study. Int J Clin Pharmacol Res 1993, 13:173-177.
73. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005, 20:533-559.
74. McClusky H.Y., Milby J.B., Switzer P.K., et al. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry 1991, 148:121-126.
75. Melo de Paula A.J. Comparative study of lormetazepam and flurazepam in the treatment of insomnia. Clin Ther 1984, 6:500-508.
76. Mendelson W.B. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992, 53(Suppl):4-7.
77. Mendelson W.B. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005, 66:469-476.
78. Mendelson W.B., Roth T., Cassella J., et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004, 8:7-17.
79. Merica H., Blois R., Gaillard J.M. Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci 1998, 10:1826-1834.
80. Milby J.B., Williams V., Hall J.N., et al. Effectiveness of combined triazolam-behavioral therapy for primary insomnia. Am J Psychiatry 1993, 150:1259-1260.
81. Morgan K., Dixon S., Mathers N., et al. Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract 2003, 53:923-928.
82. Morin C.M. Insomnia: Psychological Assessment and Management 1993, Guilford Press, New York.
83. Morin C.M., Espie C.A. Insomnia: A Clinical Guide to Assessment and Treatment 2003, Kluwer Academic/Plenum, New York.
84. Morin C.M., Culbert J.P., Schwartz S.M. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994, 151:1172-1180.
85. Morin C.M., Stone J., McDonald K., et al. Psychological management of insomnia: a clinical replication series with 100 patients. Behav Ther 1994, 25:291-309.
86. Morin C.M., Colecchi C., Stone J., et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999, 281:991-999.
87. Morin C.M., Hauri P.J., Espie C.A., et al. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999, 22:1134-1156.
88. Morin C.M., Blais F., Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia?. Behav Res Ther 2002, 40:741-752.
89. Morin C.M., Rodrigue S., Ivers H. Role of stress, arousal, and coping skills in primary insomnia. Psychosom Med 2003, 65:259-267.
90. Morin C.M., Bastien C., Guay B., et al. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry 2004, 161:332-342.
91. Morin C.M., Bootzin R.R., Buysse D.J., et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006, 29:1398-1414.
92. Morin C.M., Belanger L., Leblanc M., et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009, 169:447-453.
93. Murtagh D.R., Greenwood K.M. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995, 63:79-89.
94. National Institutes of Health National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005, 28:1049-1057.
95. National Sleep Foundation Sleep in America: A National Survey of US adults 1991, The Gallup Organization, Princeton.
96. National Sleep Foundation Sleep in America: A National Survey of US Adults 1995, The Gallup Organization, Princeton.
97. Ngen C.C., Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5mg and temazepam 20mg in insomnia. Int Clin Psychopharmacol 1990, 5:165-171.
98. Nofzinger E.A., Buysse D.J., Germain A., et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004, 161:2126-2128.
99. Nofzinger E.A., Nissen C., Germain A., et al. Regional cerebral metabolic correlates of WASO during NREM sleep in insomnia. J Clin Sleep Med 2006, 2:316-322.
100. Nowell P.D., Mazumdar S., Buysse D.J., et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997, 278:2170-2177.
101. Obermeyer W.H., Benca R.M. Effects of drugs on sleep. Neurol Clin 1996, 14:827-840.
102. Ohayon M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002, 6:97-111.
103. Ohayon M.M., Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003, 37:9-15.
104. Ozminkowski R.J., Wang S., Walsh J.K. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007, 30:263-273.
105. Pallesen S., Nordhus I.H., Kvale G., et al. Behavioral treatment of insomnia in older adults: an open clinical trial comparing two interventions. Behav Res Ther 2003, 41:31-48.
106. Perlis M.L., Merica H., Smith M.T., et al. Beta EEG activity and insomnia. Sleep Med Rev 2001, 5:363-374.
107. Perlis M.L., Smith M.T., Andrews P.J., et al. Beta/gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep 2001, 24:110-117.
108. Perlis M.L., McCall W.V., Krystal A.D., et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004, 65:1128-1137.
109. Reynolds C.F., Taska L.S., Sewitch D.E., et al. Persistent psychophysiologic insomnia: preliminary Research Diagnostic Criteria and EEG sleep data. Am J Psychiatry 1984, 141:804-805.
110. 1 antihistamines. J Clin Psychopharmacol 2002, 22:511-515.
111. Rickels K., Morris R.J., Newman H., et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983, 23:234-242.
112. Riedel B.W., Lichstein K.L. Insomnia and daytime functioning. Sleep Med Rev 2000, 4:277-298.
113. Rodenbeck A., Huether G., Ruther E., et al. Interactions between evening and nocturnal cortisol secretion and sleep parameters in patients with severe chronic primary insomnia. Neurosci Lett 2002, 324:159-163.
114. Roehrs T., Vogel G., Vogel F., et al. Dose effects of temazepam tablets on sleep. Drugs Exp Clin Res 1986, 12:693-699.
115. Roehrs T., Hollebeek E., Drake C., et al. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 2002, 53:571-576.
116. Roth T., Zorick F., Wittig R., et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 1982, 43:366-368.
117. Roth T., Wright K.P., Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006, 29:335-341.
118. Roth T., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007, 30:1555-1561.
119. Rybarczyk B., Lopez M., Benson R., et al. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging 2002, 17:288-298.
120. Rybarczyk B., Stepanski E., Fogg L., et al. A placebo-controlled test of cognitive-behavioral therapy for comorbid insomnia in older adults. J Consult Clin Psychol 2005, 73:1164-1174.
121. Sack R.L., Brandes R.W., Kendall A.R., et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000, 343:1070-1077.
122. Savard J., Simard S., Ivers H., et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 2005, 23:6083-6096.
123. Scharf M.B., Roth P.B., Dominguez R.A., et al. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol 1990, 30:461-467.
124. Scharf M.B., Roth T., Vogel G.W., et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994, 55:192-199.
125. Scharf M.B., Erman M., Rosenberg R., et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005, 28:720-727.
126. Scharf M., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008, 69:1557-1564.
127. Schutte-Rodin S., Broch L., Buysse D., et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008, 4:487-504.
128. 2C receptors in vivo. Biol Psychiatry 2000, 47:468-470.
129. Sharpley A.L., Attenburrow M.E., Hafizi S., et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005, 66:450-454.
130. Shipley J.E., Kupfer D.J., Griffin S.J., et al. Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology 1985, 85:14-22.
131. Simon G.E., VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997, 154:1417-1423.
132. Sivertsen B., Omvik S., Pallesen S., et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006, 295:2851-2858.
133. Sivertsen B., Overland S., Neckelmann D., et al. The long-term effect of insomnia on work disability: the HUNT-2 historical cohort study. Am J Epidemiol 2006, 163:1018-1024.
134. Smith M.T., Perlis M.L. Who is a candidate for cognitive-behavioral therapy for insomnia?. Health Psychol 2006, 25:15-19.
135. Smith M.T., Perlis M.L., Park A., et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002, 159:5-11.
136. Smith M.T., Huang M.I., Manber R. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev 2005, 25:559-592.
137. Soeffing J.P., Lichstein K.L., Nau S.D., et al. Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Med 2008, 9:165-171.
138. Spielman A.J., Glovinsky P.B. The varied nature of insomnia. Case Studies in Insomnia 1991, 1-15. Plenum Press, New York. P. Hauri (Ed.).
139. Spielman A.J., Saskin P., Thorpy M.J. Treatment of chronic insomnia by restriction of time in bed. Sleep 1987, 10:45-56.
140. Staner L., Ertle S., Boeijinga P., et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology 2005, 181:790-798.
141. Taylor D.J., Lichstein K.L., Weinstock J., et al. A pilot study of cognitive-behavioral therapy of insomnia in people with mild depression. Behav Ther 2007, 38:49-57.
142. Taylor D.J., Mallory L.J., Lichstein K.L., et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007, 30:213-218.
143. US Food and Drug Administration FDA Requests Label Change for all Sleep Disorder Drug Products 2007, Online. Available:. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html.
144. Vallieres A., Ivers H., Bastien C.H., et al. Variability and predictability in sleep patterns of chronic insomniacs. J Sleep Res 2005, 14:447-453.
145. Vallieres A., Morin C.M., Guay B. Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study. Behav Res Ther 2005, 43:1611-1630.
146. Verster J.C., Volkerts E.R., Schreuder A.H., et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002, 22:576-583.
147. Verster J.C., Veldhuijzen D.S., Volkerts E.R. Residual effects of sleep medication on driving ability. Sleep Med Rev 2004, 8:309-325.
148. Vgontzas A.N., Tsigos C., Bixler E.O., et al. Chronic insomnia and activity of the stress system: a preliminary study. J Psychosom Res 1998, 45(Spec. No.):21-31.
149. Vgontzas A.N., Bixler E.O., Lin H.M., et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001, 86:3787-3794.
150. Vignola A., Lamoureux C., Bastien C.H., et al. Effects of chronic insomnia and use of benzodiazepines on daytime performance in older adults. J Gerontol B Psychol Sci Soc Sci 2000, 55:P54-P62.
151. Vollrath M., Wicki W., Angst J. The Zurich study. VIII. Insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia. Eur Arch Psychiatry Neurol Sci 1989, 239:113-124.
152. Walsh J.K. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004, 65(Suppl 8):13-19.
153. Walsh J.K. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004, 27:1441-1442.
154. Walsh J.K., Erman M., Erwin C. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998, 13:191-198.
155. Walsh J.K., Vogel G.W., Scharf M., et al. A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Med 2000, 1:41-49.
156. Walsh J.K., Randazzo A.C., Frankowski S., et al. Dose-response effects of tiagabine on the sleep of older adults. Sleep 2005, 28:673-676.
157. Walsh J.K., Zammit G., Schweitzer P.K., et al. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006, 7:155-161.
158. Walsh J.K., Krystal A.D., Amato D.A., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30:959-968.
159. Wang P.S., Bohn R.L., Glynn R.J., et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001, 49:1685-1690.
160. Wilson S., Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005, 65:927-947.
161. 1H-MRS). Sleep 2008, 31:1499-1506.